FASEB Conference: Genome Engineering: Research and...
CMN Briefs
May. 7, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
CorriXR Therapeutics
Company Type: Therapeutics
Main focus: Highly selective CRISPR-Cas therapies for cancer
Company stage: Pre-clinical
Diseases: Solid tumours
Genome-editing tool: CRISPR-Cas
Funding stage: Seed Funding
Location: Newark, Delaware, USA
Website: https://www.corrixr.com/
Pipeline:
Partners:
CorriXR Therapeutics is a pre-clinical-stage therapeutics company that leverages CRISPR-Cas to specifically hit cancer cells - sparing healthy cells - by targeting cancer-specific mutations in a selected target. CorriXR's current lead target is the NRF2 gene.
